Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | LTK | P29376 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.43 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.43 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | AKT2 | P31751 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20434719 | 0.80 | CHEK1 (0.46) | CHEK1FLT3PLK3AURKBMAP4K4 | |
| SCHEMBL24427711 | 0.78 | CHEK1 (0.44) | CHEK1FLT3PLK3AURKBMAP4K4 | |
| SCHEMBL20132850 | 0.74 | CHEK1 (0.41) | CHEK1FLT3PLK3AURKBMAP4K4 | |
| SCHEMBL20132926 | 0.74 | CHEK1 (0.41) | CHEK1FLT3PLK3AURKBMAP4K4 | |
| SCHEMBL3654198 | 0.74 | CHEK1 (0.62) | CHEK1FLT3PLK3AURKBMAP4K4 | |
| SCHEMBL424795 | 0.72 | PDPK1 (0.49) | CHEK1FLT3PLK3AURKBMAP4K4 | |
| SCHEMBL29209842 | 0.72 | CHEK1 (0.39) | CHEK1FLT3PLK3AURKBMAP4K4 | |
| SCHEMBL11745813 | 0.69 | KDR (0.42) | CHEK1FLT3PLK3AURKBMAP4K4 | |
| SCHEMBL23879990 | 0.69 | CHEK1 (0.37) | CHEK1FLT3PLK3AURKBMAP4K4 | |
| SCHEMBL10370205 | 0.68 | CHEK1 (0.66) | CHEK1FLT3PLK3AURKBMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450341-B2 | Substituted indolin-2-one derivatives and their use as P38 mitogen-activated kinase inhibitors | ALMIRALL, S.A. (ES) | 2013-05-28 | — | — | US | disclosed |
| US-8450341-B2 | Substituted indolin-2-one derivatives and their use as P38 mitogen-activated kinase inhibitors | ALMIRALL, S.A. (ES) | 2013-05-28 | — | — | US | disclosed |
| US-8450341-B2 | Substituted indolin-2-one derivatives and their use as P38 mitogen-activated kinase inhibitors | ALMIRALL, S.A. (ES) | 2013-05-28 | — | — | US | disclosed |
| EP-2280953-B1 | NEW SUBSTITUTED INDOLIN-2-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL SA (ES) | 2012-05-09 | — | — | EP | disclosed |
| US-20110046097-A1 | SUBSTITUTED INDOLIN-2-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL, S.A. (ES) | 2011-02-24 | — | — | US | disclosed |
| US-20110046097-A1 | SUBSTITUTED INDOLIN-2-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL, S.A. (ES) | 2011-02-24 | — | — | US | disclosed |
| US-20110046097-A1 | SUBSTITUTED INDOLIN-2-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL, S.A. (ES) | 2011-02-24 | — | — | US | disclosed |
| EP-2280953-A1 | NEW SUBSTITUTED INDOLIN-2-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | Almirall, S.A. (ES) | 2011-02-09 | — | — | EP | disclosed |
| WO-2009132774-A1 | NEW SUBSTITUTED INDOLIN-2-ONE DERIVATIVES AND THEIR USE AS P39 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL, S. A. (ES) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009132774-A1 | NEW SUBSTITUTED INDOLIN-2-ONE DERIVATIVES AND THEIR USE AS P39 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL, S. A. (ES) | 2009-11-05 | — | — | WO | disclosed |
| EP-2113503-A1 | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors | Laboratorios Almirall, S.A. (ES) | 2009-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046097-A1 | SUBSTITUTED INDOLIN-2-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | MAPK1, MAPKAPK2, MAPK7 | CHEK1 392/4885FLT3 735/4885PLK3 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.